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How Can We Stop Cancer? 
Abstract 
Cancer is a disease that humans have been struggling to combat for centuries. It originates from the 
accumulation of several mutations over the life of a cell that causes it to evade cell death and multiply 
rapidly. It can affect any tissue in the body and can spread to other parts of the body through metastasis. 
Cancer comes in numerous shapes and sizes with different levels of aggression, growth speeds, and 
health risks. Many treatments for cancer exist today, three of the most popular being surgery, 
chemotherapy, and radiation therapy, which can be used in combinations with other treatments to best 
fight cancer. Verma et al. (2019) showed that when surgical resection is used before chemotherapy, a 
significant decrease in postoperative hospitalization lengths and 30-day mortality rates occurs, with 
correlation to trends that show increased overall survival and decreased 90-day mortality rates as well. 
Kim et al. (2018) approached treating surgery with a targeted therapy called anti-angiogenesis using the 
prodrug TA, which provided successful results in combating cancer cells by inducing apoptosis in cancer 
cells themselves as well as the endothelial cells that nourish tumors. This research can be taken into 
account by oncologists and physicians when prescribing certain treatment methods in fighting cancer, as 
these treatment options may have similar effects in treating and preventing other cancers, neoplastic 
diseases, and infections that leach nutrients from the body. 
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What is Cancer? 
Cells are the smallest subunits of life. Some can 
live on their own, while others work together to 
make up multicellular organisms. Together, cells 
build the tissues, organs, and organ systems that 
make up a multicellular organism. Each cell 
must go through the cell cycle to duplicate itself 
to produce offspring. In unicellular species, this 
makes up a whole other organism, but in 
multicellular species, this is the way that tissues 
grow. The cell cycle can be broken up into five 
different phases: G1 (growth phase), S 
(duplication of genetic information phase), G2 
(duplication of other cellular parts), mitosis 
(separation of cellular nuclei and their genetic 
contents), and cytokinesis (separation of the cells 
themselves).  
Checkpoints exist between each phase of the cell 
cycle that cells must pass to continue living. 
When a cell is stopped at a checkpoint due to the 
accumulation of mutations or other genetic 
damage, the cell either goes through the process 
to repair itself or enters another phase of the cell 
cycle, called the G0 phase. In the G0 phase of 
the cell cycle, the cell undergoes apoptosis, or 
programmed cell death. This system keeps the 
organism healthy on a cellular level by 
eliminating cells that get too old or acquire too 
many mutations to continue living a normal life.  
Cancer is defined as a group of diseases 
characterized by the uncontrollable growth and 
division of cells that have accumulated a 
significant number of mutations and have the 
ability to spread to other parts of the body. 
These cells hinder normal organ functions and 
take over the nutritional and gaseous supply to a 
body region. This occurs when a cell is able to 
bypass the checkpoints that would normally 
send it into apoptosis, which is usually caused 
by a mutation(s) that a cell misses during self-
assessment (National Cancer Institute, 2015, A).  
Cancer is usually categorized by size, 
abnormality, and invasiveness. Not all tissues 
that grow at a faster rate are considered 
cancerous metastases because they are unable to 
spread to other parts of the body. These growths 
are called neoplasms and typically result in 
benign tumors (National Cancer Institute, 2015, 
A). Neoplasms can be broken down into 
hyperplasias and dysplasias. When a normal 
tissue exhibits signs of cell proliferation and 
faster cell division, but still maintains normal 
cell organization, the growth is called 
hyperplasia, and usually results in a single-
layered benign tumor with the suffix “-oma;” the 
prefix comes from where the tumor is found. 
Dysplasia is a more serious condition because it 
exhibits more abnormality and less organization 
among the proliferation of cells. If the tumor the 
state of dysplasia produces becomes large 
enough to have multiple layers of cells, but still 
doesn’t invade nearby tissues, the tumor is 
called in situ. This form of neoplasm is usually 
treated because it is the last version of tissue 
proliferation before cancer (National Cancer 
Institute, 2015, A).  
Cancer occurs when tumors progress and 
become invasive to nearby tissues. Invasive 
tumors are typically named by their location and 
the types of cells they originate in. The most 
common type of cancer is a carcinoma, which 
forms from epithelial cells in the body. Invasive 
tumors may break off and migrate to other parts 
of the body, usually by the circulatory or 
lymphatic system. When this happens, the tumor 
is said to be malignant, and the piece of tumor 
that broke off and migrated is called a 
metastasis. Malignant cancers are much more 
difficult to treat because they affect multiple 
parts of the body and are usually spread to an 
unknown extent (National Cancer Institute, 
2015, A).  
History of treatment 
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Since its first recognition by the ancient 
philosopher and physician Hippocrates near 400 
BC, many ways to treat cancer and other 
neoplastic diseases have developed. Most of the 
advances in cancer therapy have been developed 
within the last 100 years due to breakthroughs in 
technology and medicine. Oncologists - doctors 
who specialize in cancer treatment - continue to 
expand this field of medicine through extensive 
research in strategies to fight cancer.  
Surgical resection is the oldest type of treatment 
for cancer. This involves the use of scalpels, 
lasers, hyperthermic conditions (sometimes 
using cauterization techniques for burning off 
abnormal cells), photodynamic therapy (the use 
of drugs activated by light that kill surrounding 
tissues), or the application of liquid nitrogen or 
argon gas (to freeze and destroy abnormal 
tissue). Surgery usually requires the use of local, 
regional, or general anesthetics to cause loss of 
feeling for pain in small parts, large parts, and 
the entire body, respectively. Under general 
anesthesia, patients lose consciousness and 
exhibit symptoms similar to a deep sleep, which 
allows the surgeon to operate safely. Surgical 
resection can be performed by extracting a 
tumor and nearby tissues through a large cut in 
open surgery, or can be done through multiple 
small cuts, extracting small parts of the tumor 
multiple times using tools and monitors in 
minimally invasive surgery. Due to the fact that 
the surgeon is unable to see the inside of the 
body through small cuts in minimally invasive 
surgery, they use a laparoscope (a small tube 
with a tiny camera on it to project video of the 
inside of the body to a monitor for the surgeon 
to see) to complete the resection. Minimally 
invasive surgery requires less time to recover 
because smaller incisions are used than during 
open surgery, which tend to heal at a faster rate. 
Surgical resection can also be performed for 
multiple purposes: curative surgery aims to 
remove the entire tumor to cure the patient of 
cancer; preventive surgery involves the removal 
of tissue that has the potential to become cancer, 
such as dysplasia or in-situ tumor; diagnostic 
resection takes one part of a cell growth out of 
the body to study for cancerous properties; 
debulking resection extracts a large part of a 
tumor to minimize its size; palliative care 
includes the use of surgery to ease pain caused 
by cancer; supportive therapy aims to help other 
cancer treatments work more effectively; 
restorative surgery is used to rebuild a patient’s 
body through plastic surgery to restore normal 
bodily characteristics (National Cancer Institute, 
2015, B). Marinho et al. (2018) performed a 
study that recorded cancer patients’ qualities of 
life before surgery and quality of recovery after, 
finding 31 out of 138 surveyed patients having 
poor quality of recovery. Patients who had a 
poor quality of recovery also had significantly 
poor qualities of life, frailness, and high cardiac 
risk factors, which are all characteristics that 
oncologists need to consider when 
recommending surgical resection as a treatment 
for cancer. Despite this, surgical resection 
remains the preferred treatment type because of 
its diversity, conformity, and ability to be used 
in conjunction with other methods to treat 
cancer.  
Chemotherapy, or chemo, is the second most 
common way to treat cancer. It involves the use 
of drugs to stop or slow cancer growth. This can 
help oncologists treat cancer by curing it, 
lessening its chance of return, or reducing the 
size of tumors that cause pain or other 
symptoms. Chemotherapy is typically used in 
conjunction with other forms of therapy. When 
it is used before another form of treatment 
(mainly to decrease the size of a tumor), it is 
called neoadjuvant chemotherapy. Conversely, 
adjuvant chemotherapy is defined as 
chemotherapy used after another form of cancer 
treatment. It can be administered in a multitude 
of ways depending on cancer type, drug 
conformity, and medicinal accessibility: oral (by 
mouth), intravenous (directly into a vein), 
injection (by a hypodermic needle), or topically 
(by rubbing it into the skin). Chemotherapy is a 
non-invasive treatment but has other side effects 
because it does not differentiate between healthy 
and cancer cells. This typically affects normal 
cells in the body that divide fast, such as cells 
that make up hair and the linings of the mouth, 
stomach, and intestine, causing hair loss, mouth 
sores, ulcers, and nausea. Fatigue is another side 
effect common with chemotherapy treatment 
because healthy body cells slow their rates of 
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activity and do not perform at optimal metabolic 
capacities (National Cancer Institute, 2015, C).  
Another common way to treat cancer is through 
radiation therapy, or radiotherapy. This is the 
exposure of the body to high levels of radiation 
to reduce tumor sizes and destroy cancer cells. 
Radiation therapy can be performed by using an 
external beam of radiation to deliver 
concentrated doses of radiation to a localized 
area or by using an internal source of radiation. 
External beam radiation can be delivered by two 
methods: conventionally fractionated radiation 
therapy and stereotactic ablative radiation 
therapy. Conventionally fractionated radiation 
therapy uses a broad, low-powered beam of 
radiation administered in multiple doses to 
destroy cancer cells while stereotactic ablative 
radiation therapy involves the use of a highly 
accurate, high-powered, concentrated beam of 
radiation to eliminate cancer cells (National 
Cancer Institute, 2015, D). Verma et al. (2018) 
concluded that no significant difference exists in 
the overall survival rates between patients who 
received either treatment for inoperable stage I 
small cell lung cancer. Although, stereotactic 
ablative radiation therapy is the favored external 
form of radiotherapy because it is more cost-
effective, conformative, and convenient than 
conventionally fractionated radiation therapy 
while producing relatively equal results of 
treatment. On the other hand, internal radiation 
therapy also has two forms: brachytherapy and 
systemic radiation therapy. Brachytherapy uses a 
solid source of radiation that is implanted in the 
body near or in the tumor to release radiation 
over time, while systemic radiation therapy 
involves the introduction of a radioactive liquid 
into the system through ingestion, hypodermal 
injection, or intravenous solution, to travel 
through the blood to reach and destroy cancer 
cells. Radiation therapy is very similar to 
chemotherapy in regards to side effects, 
frequency of being combined with other 
treatments, and that it also affects healthy tissues 
within the area of treatment, but is different in 
that it has the ability to be more localized and is 
associated with lifetime dose limits to avoid the 
development of other health issues in areas that 
are treated with radiation more than once 
(National Cancer Institute, 2015, D).  
Among the three main ways to treat cancer 
described above, many other treatment options 
exist that are relatively new. Immunotherapy is a 
cancer treatment that aids the immune system in 
battling cancer. Targeted therapy treats cancer 
by targeting its methods of growing, dividing, 
and spreading. Hormonal therapy blocks the 
body’s ability to produce hormones that some 
cancers use to grow. Virotherapy uses oncolytic 
viruses that have had their virulence factors 
removed to attack cancer cells while ignoring 
normal cells (National Cancer Institute, 2015, 
E). Virotherapy works very well when paired 
with immunotherapy because defects in immune 
signaling within tumors can be used for 
oncolytic viruses to target for destruction and 
self-replication (Kadia, 2016). Another 
supportive treatment of cancer includes stem cell 
transplants, which replace the stem cells in a 
patient’s body that have been destroyed by other 
treatments (National Cancer Institute, 2015, E). 
Cancer treatments are constantly being 
developed and tested by oncologists around the 
world in the international fight against cancer.  
As with any disease, one of the most effective 
ways to combat cancer is to prevent it. A 
scientific review published by Colditz et al. 
(2012) shows the potential for our society to 
prevent cancer to be at a level that could cut 
cancer cases by more than half (54.5%). Ways to 
prevent cancer include quitting smoking, 
implementing healthier diets, increasing 
exercise, avoiding obesity, acquiring 
vaccinations against cancer-causing viruses, 
avoiding UV and other ionizing radiation, 
decreasing irresponsible consumption of alcohol 
and prescription medications, and decreasing 
pollution. Obstacles for the success of such 
prevention include societal skepticism of the 
preventability of cancer, the lack of research in 
cancer prevention (rather than treatment), and 
the absence of an infrastructure that can be held 
accountable to educate the public.  
In this work, I examine and review studies that 
address the different treatments to help cure the 
family of diseases called cancer and keep it from 
returning. Using an approach that compares 
overall survival rates, postoperative 
hospitalization lengths, 30/90-day mortality 
3
Current: How Can We Stop Cancer?
Published by Fisher Digital Publications, 2020
rates, and 30-day readmission rates between 
cancer patients treated with induction 
chemotherapy and then surgical resection versus 
up-front resection followed by postoperative 
chemotherapy, Verma et al. (2019) showed that 
patients who received up-front surgical resection 
followed by postoperative chemotherapy had 
significantly shorter postoperative 
hospitalization and lower 30-day mortality, as 
well as correlation to increased median overall 
survival and decreased 90-day mortality. In 
addition, Kim et al. (2018) used targeted therapy 
through the injection of a hypoxia-responsive, 
anti-angiogenic prodrug (TA) into strains of 
normal and cancerous cells under normoxic and 
hypoxic conditions in vitro to show that, when 
activated in hypoxic cancer cells, TA causes a 
reduction in topoisomerase I, COX-2, and 
VEGF gene expression, leading to significantly 
increased toxicity and decreased cancer cell 
viability while normal cells were left relatively 
unaffected. Taken together, these studies both 
contribute to the eradication of cancer and 
suggest successful ways to fight and end cancer, 
as well as other neoplastic diseases, while 
increasing overall survivability for patients.  
R/PC may be a more successful combination 
of treatment methods 
In the past 50 years, it has become very common 
for surgical resection and chemotherapy to be 
used together to treat cancer. If neoadjuvant 
chemotherapy is administered before surgery, 
the treatment combination is called induction 
chemotherapy followed by surgical resection, 
which is regularly abbreviated as IC/R. 
Advantages of this method would be having the 
ability to reduce the size of a tumor before its 
extraction, which also may minimize how 
invasive the surgery after chemo is. Up-front 
resection followed by postoperative 
chemotherapy, or R/PC treatment, involves the 
use of adjuvant chemotherapy after surgical 
resection. The advantages of this procedure 
include the ability to prevent cancer from 
returning using chemotherapy after the surgery 
removes the majority - if not the entirety - of the 
tumor. In addition, it is more typical to provide 
weaker, less harmful chemotherapy medication 
in R/PC treatment than in IC/R treatment 
because IC/R treatment relies more heavily on 
the use of chemotherapy to remove cancerous 
tissue (Verma 2019).  
To determine the best treatment or combination 
of treatments to fight cancer, Verma et al. 
(2019) examined the data for two different 
combinations of treatments for patients with 
malignant pleural mesothelioma (IC/R and 
R/PC). Malignant pleural mesothelioma is an 
aggressive and deadly form of cancer that 
resides in the mesothelium, which is a thin layer 
of tissue that covers most internal organs in the 
thoracic and abdominal cavities. It is caused by 
the inhalation and migration of asbestos fibers 
from the air to the pleural lining, causing 
inflammation, tissue damage, and scarring. 
Since asbestos is considered a carcinogen, it has 
the capacity to cause mutations in the tissues 
that are exposed to it, posing a greater risk for 
the development of cancer. In addition, the 
asbestos can also cause nearby tissues to have 
similar symptoms to those of the mesothelium 
and trigger the development of cancers in the 
lung, peritoneum, and pericardium. Comparative 
analysis techniques were used to study the 
overall survival rates, lengths of postoperative 
hospitalization, 30/90-day mortality rates, and 
30-day readmission rates between IC/R and 
R/PC treated patients that were documented in 
the National Cancer Database.  
Of the 361 malignant pleural mesothelioma 
patients, 182 were treated using IC/R and 179 
were treated using R/PC techniques. R/PC 
patients were found to have a correlation to 
increased median overall survival and decreased 
90-day mortality rates. In addition, R/PC 
patients had significantly decreased 
postoperative hospitalization lengths (6 days vs. 
7 days, p = 0.001) and 30- day mortality rates 
(0.0% vs. 3.3%, p = 0.020) on 95% confidence 
intervals. There was no statistical difference in 
30-day readmission rates for patients between 
each treatment combination. Therefore, R/PC is 
a more successful treatment combination than 
IC/R for treating malignant pleural 
mesothelioma (Verma 2019), and may show 
increased success in treating similar cancers.  
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Anti-angiogenic prodrugs significantly 
decrease Cancer viability 
The circulatory system is a vital body system in 
multicellular organisms. It serves many 
functions, including the transport of nutrients, 
ions, gases, metabolites, and metabolic wastes 
around the body through blood vessels. 
Angiogenesis is the formation of blood 
vasculature throughout the various tissues of our 
body to aid in the delivery and removal of the 
molecules that are vital to many life processes. It 
is stimulated by growth factors and hormones 
throughout the development of an organism to 
maintain vascular coverage through the entirety 
of the body. This is important to prevent the 
starvation or buildup of toxic substances in local 
areas of the body. Without the circulatory 
system, the internal cells of many multicellular 
organisms would never acquire essential 
molecules for life and, in turn, would starve or 
accumulate metabolic wastes that would not be 
transported away from internal tissues.  
As with any body cell, cancer cells need vital 
nutrients essential to life to continue to grow and 
divide. They also require the removal of waste 
products. To grow inside a multicellular 
organism, tumors must acquire nutrients and get 
rid of metabolic wastes using blood vessels. 
They attract blood vessels and induce 
angiogenesis by releasing a growth factor called 
VEGF (vascular endothelial growth factor). This 
growth factor stimulates the formation of new 
vasculature towards the tumor and capillaries to 
grow around it. The constant flow of nutrient, 
oxygen-filled blood to the tumor allows it to 
obtain nutrients from the body to grow and 
divide. The blood also cleanses the cancer cells 
by removing metabolic waste buildup, further 
supporting it. Finally, blood vessels that connect 
to the tumor provide a route for the tumor to 
metastasize and travel to other parts of the body 
and form other cancerous growths (Kim 2018).  
Anti-angiogenesis is a form of targeted therapy 
that aims to starve cancerous tumors by cutting 
off their supply lines, inhibiting angiogenesis 
locally to prevent tumors from siphoning 
nutrients and oxygen from the body and leaving 
it with metabolic wastes. Like 
chemotherapy/radiation therapy, many 
chemicals involved with anti-angiogenic therapy 
are toxic to neighboring normal cells (Wang 
2015). Kim et al. (2018) employed anti-
angiogenic techniques to destroy cancer cells in 
their experiment by injecting a hypoxia-induced, 
anti-angiogenic prodrug (denoted as TA) into 
strains of normal and cancerous cells under 
normoxic (21% O2) and hypoxic (1% O2) 
conditions in vitro. They observed the 
differences in cell viability (by cytotoxicity) and 
gene expression levels to determine the effect 
TA had on the injected tissues.  
Under hypoxic conditions (when TA becomes 
active), the gene expression of topoisomerase I, 
COX-2, and VEGF was decreased in cancer 
cells. This contributes to the apoptosis of cancer 
cells themselves and the vascular tissue 
surrounding the tumor. Topoisomerase I is a 
protein that aids in the rewinding of DNA during 
replication, and without it, cancer cells aren’t 
able to live, grow, and divide. Therefore, 
decreased levels of topoisomerase I show that 
TA contributes to cell death in cancer cells when 
activated by hypoxic conditions. In addition, 
COX- 2 (a gene associated with inflammation 
and vascular growth) and VEGF (growth factor 
associated with vascular development) also 
exhibited decreased levels in hypoxic conditions 
when exposed to TA, supporting the idea that TA 
contributes to anti-angiogenesis. Other data from 
Kim’s experiment suggest that TA only produces 
lethal effects in hypoxic cancer cells, not 
harming hypoxic normal cells in any significant 
way. Hypoxic cancer cells significantly dropped 
in viability from 100% to 40% with just a 10 
micromolar concentration of TA, as well as 
decreasing by a factor of two with each 
incremental increase in TA concentration, while 
hypoxic normal cells only decreased to a 
minimum of 90% viability (p < 0.05). In this 
experiment, TA shows that it is successful in 
combating cancer using its apoptotic and anti-
angiogenic effects on cancer cells while leaving 
normal cells virtually untouched (Kim 2018). 
This may also hold true in human cancers, and 
should be explored more.  
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The most successful ways to combat cancer 
Cancer is a disease that humans have been 
struggling to combat for centuries. Recently, the 
treatments that have already been developed by 
oncologists to fight cancer have been used in 
combinations with other treatments to best fight 
cancer. This popular treatment method 
implements the use of drug cocktails and 
multiple treatment plans to attack cancer through 
various mediums. Verma et al. (2019) showed 
that when surgical resection is used before 
chemotherapy, a significant decrease in 
postoperative hospitalization lengths and 30-day 
mortality rates occurs, with correlation to trends 
that show increased overall survival and 
decreased 90-day mortality rates as well. This 
type of study helps oncologists and physicians 
decide what the best combination of treatment 
options is so an educated decision can be made 
before choosing to randomly mix multiple 
therapies.  
Research into novel treatment methods is very 
important as well. Kim et al. (2018) approached 
treating surgery with a new targeted therapy 
involving anti-angiogenesis using the prodrug 
TA, which provided successful results in 
combating cancer cells in vitro by inducing 
apoptosis in cancer cells themselves as well as 
the blood vasculature that nourishes tumors. 
This experiment was very significant for the 
development of this new therapy type, which 
will be very helpful if/when approved for testing 
in vivo in human bodies someday. Since no 
universal intervention exists for all cancers yet, 
research into new ways to destroy cancer is 
conducive to the progression of the field of 
study. When paired with other new or old 
treatment methods, novel therapies like anti-
angiogenesis could someday lead oncologists to 
the cure for cancer.  
Lastly, the results from the aforementioned 
studies, along with the findings of other 
oncological researchers, can be taken into 
account by physicians and oncologists when 
prescribing certain treatment methods or 
combinations for treating cancers, neoplastic 
diseases, or other infections that leach nutrients 
from the body, as these treatment options may 
have similar effects in treating and preventing 
these types of medical issues. Studies like these 
promote the use of Western medicine and 
support the advancement of our biological and 
medical understanding of the human body.  
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